Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently unapproved by the MHRA, EMA, or FDA for routine clinical use
In addition, comorbid conditions such as hypertension and obesity further elevate risk
Emerging data shows benefits for osteoarthritis, kidney health, and sleep apnea
Reema Arora (MBBS, MSc Facial Aesthetics, UK) following structured medical assessment to ensure safety, suitability, and individualised care
Ready to Manage Ozempic the Right Way
UPB Reta 10MG (Triple Agonist) 5.00 out of 5 based on 9 customer ratings $159.99 Original price was: $159.99.$129.99Current price is: $129.99